Planned transition paves a smooth path for the fall opening of the new
Reno, Nev. – As part of a planned transition, the Whittemore Peterson
Institute (WPI) announces the national search for a full time Medical
Director as Dr. Daniel Peterson retires from this position. Dr.
Peterson, a pioneering physician in describing methods of diagnosing,
managing and treating "Myalgic Encephalomyelitis (ME/CFS)", was one of
the first physicians to identify this disease in the United States.
Annette Whittemore, founder and president of the Whittemore Peterson
Institute, remarked, "Dr. Peterson was a central figure in the
establishment of the Whittemore Peterson Institute. We are deeply
grateful to him for his significant advice and support through the
development of the Institute."
Dr. Peterson will continue his internal medicine practice in Incline
Village, Nevada. "I am extremely proud to have been a part of the
creation of this medical research Institute which promises to bring
exciting new answers to patients with complex neuroimmune diseases,"
stated Dr. Peterson.
The WPI will soon begin a national search for a new full-‐time
medical director and practicing physician with extensive experience in
infectious disease, clinical trials and medical management.
The Whittemore Peterson Institute will move into a new
100,000-‐square-‐foot state-‐of-‐the art research and medical
Center for Molecular Medicine, at the University of Nevada in the fall
of 2010. Led by the research of Dr. Judy Mikovits, WPI will be the
first Institute in the world dedicated to neuro-‐immune diseases
integrating a comprehensive program of patient treatment, basic
research, clinical trials and medical education.
To learn more about the institute and ongoing research, please visit
About The Whittemore Peterson Institute
Located within the University of Nevada School of Medicine's Center
for Molecular Medicine, the Whittemore Peterson Institute will be the
nation's first comprehensive translational research facility dedicated
to the research and treatment of neuro-‐immune diseases when it opens
in September 2010.